Overview

Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)

Status:
Completed
Trial end date:
2008-02-29
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of MNTX in participants who have undergone segmental colectomy and to assess if the time between the end of surgery and the first bowel movement is significantly shorter in the MNTX regimen than the equivalent assessment using a placebo regimen.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Bromides
Methylnaltrexone
Naltrexone